| Literature DB >> 27476457 |
C E French1, C Thorne1, L Byrne1, M Cortina-Borja1, P A Tookey1.
Abstract
OBJECTIVES: Despite very low rates of vertical transmission of HIV in the UK overall, rates are higher among women starting antenatal antiretroviral therapy (ART) late. We investigated the timing of key elements of the care of HIV-positive pregnant women [antenatal care booking, HIV laboratory assessment (CD4 count and HIV viral load) and antenatal ART initiation], to assess whether clinical practice is changing in line with recommendations, and to investigate factors associated with delayed care.Entities:
Keywords: zzm321990HIVzzm321990; antenatal care; antiretroviral therapy; pregnancy; prevention of mother-to-child transmission
Mesh:
Year: 2016 PMID: 27476457 PMCID: PMC5298001 DOI: 10.1111/hiv.12410
Source DB: PubMed Journal: HIV Med ISSN: 1464-2662 Impact factor: 3.180
Pregnancy characteristics stratified by timing of HIV diagnosis
| Characteristic | Diagnosed prior to current pregnancy ‐ not on ART at conception | Diagnosed prior to current pregnancy ‐ on ART at conception | Diagnosed prior to current pregnancy (irrespective of ART status) | Newly diagnosed during current pregnancy | Total (all pregnancies) |
|---|---|---|---|---|---|
| Total | 1601 | 2886 | 4527 | 1166 | 5693 (100) |
| Time period | |||||
| 2009–2011 | 1049 (65.5) | 1611 (55.8) | 2686 (59.3) | 820 (70.3) | 3506 (61.6) |
| 2012–2014 | 552 (34.5) | 1275 (44.2) | 1841 (40.7) | 346 (29.7) | 2187 (38.4) |
| Maternal age at delivery | |||||
| < 25 years | 209 (13.1) | 140 (4.9) | 355 (7.8) | 177 (15.2) | 532 (9.3) |
| 25–34 years | 967 (60.4) | 1479 (51.2) | 2472 (54.6) | 727 (62.3) | 3199 (56.2) |
| ≥ 35 years | 425 (26.5) | 1267 (43.9) | 1700 (37.6) | 262 (22.5) | 1962 (34.5) |
| Maternal region of origin | |||||
| UK/Ireland | 276 (17.4) | 331 (11.6) | 612 (13.7) | 157 (13.7) | 769 (13.7) |
| Europe | 80 (5.0) | 107 (3.8) | 190 (4.2) | 77 (6.7) | 267 (4.8) |
| Eastern Africa | 642 (40.5) | 1386 (48.7) | 2048 (45.8) | 397 (34.7) | 2445 (43.5) |
| Middle Africa | 100 (6.3) | 190 (6.7) | 293 (6.6) | 49 (4.3) | 342 (6.1) |
| Western Africa | 311 (19.6) | 498 (17.5) | 813 (18.2) | 301 (26.3) | 1114 (19.8) |
| Southern Africa | 77 (4.9) | 130 (4.6) | 209 (4.7) | 61 (5.3) | 270 (4.8) |
| Africa (unspecified) | 11 (0.7) | 30 (1.1) | 41 (0.9) | 18 (1.6) | 59 (1.1) |
| Elsewhere | 88 (5.6) | 174 (6.1) | 265 (5.9) | 85 (7.4) | 350 (6.2) |
| Reporting region | |||||
| London | 641 (40.2) | 1279 (44.4) | 1926 (42.6) | 488 (42) | 2414 (42.5) |
| Midlands and the East | 409 (25.6) | 649 (22.5) | 1073 (23.8) | 284 (24.4) | 1357 (23.9) |
| North | 253 (15.9) | 414 (14.4) | 677 (15) | 153 (13.2) | 830 (14.6) |
| South | 189 (11.8) | 394 (13.7) | 591 (13.1) | 150 (12.9) | 741 (13.1) |
| Wales, Scotland and Northern Ireland | 103 (6.5) | 145 (5) | 249 (5.5) | 87 (7.5) | 336 (5.9) |
| Parity | |||||
| Nulliparous | 300 (19.6) | 559 (20.4) | 864 (20.1) | 555 (50.7) | 1419 (26.3) |
| One previous birth | 592 (38.7) | 1018 (37.2) | 1626 (37.9) | 323 (29.5) | 1949 (36.2) |
| Two previous births | 400 (26.1) | 740 (27.0) | 1145 (26.7) | 145 (13.2) | 1290 (23.9) |
| At least three previous births | 238 (15.6) | 419 (15.3) | 660 (15.4) | 72 (6.6) | 732 (13.6) |
| Earliest CD4 count | |||||
| ≥ 500 cells/μL | 484 (33.1) | 1163 (44.2) | 1654 (40.3) | 306 (27.9) | 1960 (37.7) |
| 350–499 cells/μL | 432 (29.5) | 800 (30.4) | 1238 (30.2) | 258 (23.6) | 1496 (28.8) |
| 200–349 cells/μL | 368 (25.2) | 517 (19.7) | 886 (21.6) | 317 (28.9) | 1203 (23.1) |
| < 200 cells/μL | 178 (12.2) | 149 (5.7) | 327 (8.0) | 214 (19.5) | 541 (10.4) |
| Earliest viral load | |||||
| < 50 copies/mL | 275 (18.1) | 2350 (85.9) | 2641 (61.8) | 145 (12.8) | 2770 (51.4) |
| 50–29 999 copies/mL | 931 (61.4) | 342 (12.5) | 1279 (29.9) | 700 (61.6) | 1973 (36.6) |
| 30 000–99 999 copies/mL | 213 (14.0) | 25 (0.9) | 238 (5.6) | 168 (14.8) | 406 (7.5) |
| ≥ 100 000 copies/mL | 98 (6.5) | 18 (0.7) | 116 (2.7) | 124 (10.9) | 240 (4.5) |
ART, antiretroviral therapy.
Values are n (%).
Group combines the first two groups presented in the table (n = 1601 + 2886) plus 40 pregnancies with missing information on ART status at conception.
Earliest antenatal measurement in that pregnancy, not restricted to measurements taken prior to ART initiation.
Figure 1Gestation at antenatal care booking for (a) women diagnosed with HIV prior to that pregnancy and (b) women newly diagnosed with HIV during that pregnancy.
Univariable and multivariable analyses of factors associated with booking late for antenatal care (≥ 13 gestational weeks), stratified by timing of HIV diagnosis
| Diagnosed prior to current pregnancy | Newly diagnosed during current pregnancy | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Booked at ≥ 13 weeks/total (%) | OR (95% CI) |
| aOR (95% CI) |
| Booked at ≥ 13 weeks/total (%) | OR (95% CI) |
| aOR (95% CI) |
| |
| Time period of delivery | ||||||||||
| 2009–2011 | 1027/2415 (42.5) | 1 | 390/748 (52.1) | 1 | 1 | |||||
| 2012–2014 | 600/1681 (35.7) | 0.75 (0.66–0.85) | < 0.001 | 0.74 (0.64–0.86) | < 0.001 | 163/318 (51.3) | 0.97 (0.74–1.26) | 0.792 | 1.00 (0.74–1.34) | 0.978 |
| Maternal age at delivery | ||||||||||
| < 25 years | 126/318 (39.6) | 1 | 84/162 (51.9) | 1 | ||||||
| 25–34 years | 855/2232 (38.3) | 0.95 (0.74–1.21) | 0.654 | – | 343/666 (51.5) | 0.99 (0.70–1.39) | 0.936 | – | ||
| ≥ 35 years | 646/1546 (41.8) | 1.09 (0.85–1.40) | 0.481 | – | – | 126/238 (52.9) | 1.04 (0.70–1.56) | 0.830 | – | – |
| Maternal region of origin | ||||||||||
| UK/Ireland | 177/551 (32.1) | 1 | 1 | 48/140 (34.3) | 1 | 1 | ||||
| Europe | 64/173 (37.0) | 1.24 (0.86–1.79) | 0.249 | 1.51 (1.01–2.26) | 0.044 | 31/70 (44.3) | 1.52 (0.85–2.74) | 0.160 | 1.54 (0.81–2.95) | 0.188 |
| Eastern Africa | 758/1823 (41.6) | 1.50 (1.22–1.85) | < 0.001 | 1.61 (1.28–2.02) | < 0.001 | 197/351 (56.1) | 2.45 (1.63–3.69) | < 0.001 | 2.73 (1.74–4.29) | < 0.001 |
| Middle Africa | 130/264 (49.2) | 2.05 (1.50–2.81) | < 0.001 | 2.24 (1.59–3.14) | < 0.001 | 33/48 (68.8) | 4.22 (2.09–8.52) | < 0.001 | 3.84 (1.82–8.13) | < 0.001 |
| Western Africa | 304/763 (39.8) | 1.40 (1.10–1.77) | 0.006 | 1.65 (1.27–2.14) | < 0.001 | 159/284 (56) | 2.44 (1.60–3.71) | < 0.001 | 2.14 (1.33–3.43) | 0.002 |
| Southern Africa | 81/190 (42.6) | 1.57 (1.11–2.23) | 0.012 | 1.65 (1.13–2.43) | 0.010 | 39/58 (67.2) | 3.93 (2.05–7.54) | < 0.001 | 3.92 (1.90–8.05) | < 0.001 |
| Africa (region unspecified) | 14/37 (37.8) | 1.29 (0.63–2.64) | 0.492 | 1.46 (0.68–3.16) | 0.335 | 7/18 (38.9) | 1.22 (0.44–3.35) | 0.700 | 1.52 (0.49–4.73) | 0.467 |
| Elsewhere | 84/248 (33.9) | 1.08 (0.78–1.51) | 0.639 | 1.26 (0.88–1.81) | 0.207 | 30/78 (38.5) | 1.20 (0.67–2.13) | 0.538 | 1.25 (0.67–2.33) | 0.490 |
| Reporting region | ||||||||||
| London | 656/1852 (35.4) | 1 | 1 | 265/459 (57.7) | 1 | 1 | ||||
| Midlands and the East | 353/836 (42.2) | 1.33 (1.13–1.58) | 0.001 | 1.42 (1.17–1.71) | < 0.001 | 118/240 (49.2) | 0.71 (0.52–0.97) | 0.031 | 0.65 (0.45–0.93) | 0.021 |
| North | 285/651 (43.8) | 1.42 (1.18–1.71) | < 0.001 | 1.36 (1.10–1.67) | 0.004 | 58/148 (39.2) | 0.47 (0.32–0.69) | < 0.001 | 0.39 (0.25–0.59) | < 0.001 |
| South | 212/512 (41.4) | 1.29 (1.05–1.58) | 0.015 | 1.53 (1.22–1.93) | < 0.001 | 64/133 (48.1) | 0.68 (0.46–1.00) | 0.050 | 0.66 (0.42–1.03) | 0.069 |
| Wales, Scotland and Northern Ireland | 119/237 (50.2) | 1.84 (1.40–2.42) | < 0.001 | 2.06 (1.50–2.84) | < 0.001 | 46/83 (55.4) | 0.91 (0.57–1.46) | 0.695 | 1.18 (0.69–2.01) | 0.545 |
| Parity | ||||||||||
| Nulliparous | 254/799 (31.8) | 1 | 1 | 265/525 (50.5) | 1 | 1 | ||||
| One previous birth | 541/1459 (37.1) | 1.26 (1.05–1.52) | 0.012 | 1.19 (0.97–1.45) | 0.091 | 150/293 (51.2) | 1.03 (0.77–1.37) | 0.844 | 1.05 (0.77–1.44) | 0.742 |
| Two previous births | 460/1033 (44.5) | 1.72 (1.42–2.09) | < 0.001 | 1.60 (1.30–1.98) | < 0.001 | 78/126 (61.9) | 1.59 (1.07–2.37) | 0.022 | 1.87 (1.21–2.87) | 0.004 |
| At least three previous births | 297/605 (49.1) | 2.07 (1.66–2.58) | < 0.001 | 1.92 (1.52–2.44) | < 0.001 | 36/64 (56.3) | 1.26 (0.75–2.13) | 0.384 | 1.29 (0.73–2.29) | 0.377 |
| On ART at conception | ||||||||||
| No | 650/1458 (44.6) | 1 | 1 | n/a | – | n/a | ||||
| Yes | 964/2602 (37.0) | 0.73 (0.64–0.84) | < 0.001 | 0.70 (0.61–0.82) | < 0.001 | n/a | – | – | n/a | – |
| Earliest CD4 count | ||||||||||
| ≥ 500 cells/μL | 557/1492 (37.3) | 1 | 1 | 138/278 (49.6) | 1 | 1 | ||||
| 350–499 cells/μL | 460/1125 (40.9) | 1.16 (0.99–1.36) | 0.067 | 1.12 (0.95–1.33) | 0.183 | 120/235 (51.1) | 1.06 (0.75–1.50) | 0.748 | (dropped) | – |
| 200–349 cells/μL | 330/796 (41.5) | 1.19 (1.00–1.42) | 0.057 | 1.10 (0.91–1.33) | 0.331 | 153/292 (52.4) | 1.12 (0.80–1.55) | 0.510 | 0.93 (0.64–1.36) | 0.706 |
| < 200 cells/μL | 152/300 (50.7) | 1.72 (1.34–2.22) | < 0.001 | 1.67 (1.27–2.18) | < 0.001 | 105/196 (53.6) | 1.17 (0.81–1.69) | 0.399 | 0.95 (0.66–1.36) | 0.781 |
| Earliest viral load | ||||||||||
| < 30 000 copies/mL | 1416/3552 (39.9) | 1 | 402/775 (51.9) | 1 | ||||||
| 30 000–99 999 cells/μL | 101/213 (47.4) | 1.36 (1.02–1.81) | 0.034 | – | 81/156 (51.9) | 1.00 (0.71–1.41) | 0.991 | – | ||
| ≥ 100 000 cells/μL | 45/106 (42.5) | 1.11 (0.74–1.67) | 0.606 | – | – | 57/111 (51.4) | 0.98 (0.66–1.46) | 0.918 | – | – |
aOR, adjusted odds ratio; ART, antiretroviral therapy; CI, confidence interval; OR, odds ratio.
The multivariable model for pregnancies in previously diagnosed women included 3493 observations (and analyses were adjusted for 3149 clusters; i.e. the 3493 pregnancies occurred in 3149 women).
The multivariable model for pregnancies in women diagnosed during their current pregnancy included 938 observations.
Earliest antenatal measurement in that pregnancy, not restricted to measurements prior to ART initiation.
Figure 2Cumulative probability of initiating antenatal antiretroviral therapy (ART) by gestational week, stratified by timing of HIV diagnosis.
Univariable and multivariable Cox proportional hazards analyses of factors associated with shorter time to antenatal antiretroviral therapy (ART) initiation, stratified by timing of HIV diagnosis
| Characteristic | Diagnosed prior to current pregnancy | Newly diagnosed during current pregnancy | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
| HR (95% CI) |
| aHR (95% CI) |
|
| HR (95% CI) |
| aHR (95% CI) |
| |
| Time period | ||||||||||
| 2009–2011 | 1022 | 1 | 1 | 796 | 1 | 1 | ||||
| 2012–2014 | 521 | 1.24 (1.10–1.39) | < 0.001 | 1.28 (1.12–1.46) | < 0.001 | 326 | 1.20 (1.05–1.37) | 0.006 | 1.34 (1.15–1.55) | < 0.001 |
| Maternal age at delivery | ||||||||||
| < 25 years | 203 | 1 | 173 | 1 | 1 | |||||
| 25–34 years | 932 | 0.98 (0.83–1.16) | 0.800 | – | 701 | 1.12 (0.95–1.33) | 0.185 | 1.15 (0.95–1.40) | 0.159 | |
| ≥ 35 years | 408 | 0.97 (0.81–1.16) | 0.734 | – | – | 248 | 1.31 (1.08–1.60) | 0.007 | 1.17 (0.93–1.47) | 0.192 |
| Maternal region of origin | ||||||||||
| UK/Ireland | 270 | 1 | – | 154 | 1 | 1 | ||||
| Europe | 78 | 1.09 (0.85–1.41) | 0.483 | – | – | 71 | 0.87 (0.66–1.16) | 0.357 | 0.75 (0.55–1.02) | 0.068 |
| Eastern Africa | 616 | 1.05 (0.90–1.23) | 0.520 | – | – | 385 | 0.93 (0.77–1.13) | 0.473 | 0.75 (0.60–0.93) | 0.010 |
| Middle Africa | 96 | 0.96 (0.73–1.26) | 0.784 | – | – | 45 | 0.91 (0.65–1.27) | 0.591 | 0.82 (0.56–1.20) | 0.309 |
| Western Africa | 303 | 0.93 (0.78–1.11) | 0.436 | – | – | 294 | 0.73 (0.60–0.89) | 0.002 | 0.60 (0.48–0.76) | < 0.001 |
| Southern Africa | 74 | 1.08 (0.86–1.35) | 0.499 | – | – | 58 | 0.77 (0.56–1.04) | 0.090 | 0.68 (0.47–0.97) | 0.032 |
| Africa (region unspecified) | 10 | 1.01 (0.68–1.51) | 0.951 | – | – | 15 | 0.98 (0.58–1.67) | 0.939 | 0.50 (0.25–1.00) | 0.049 |
| Elsewhere | 83 | 1.02 (0.80–1.31) | 0.881 | – | – | 81 | 1.17 (0.89–1.54) | 0.249 | 0.92 (0.68–1.25) | 0.612 |
| Reporting region | ||||||||||
| London | 621 | 1 | 1 | 473 | 1 | 1 | ||||
| Midlands and the East | 394 | 1.17 (1.02–1.33) | 0.021 | 1.13 (0.96–1.32) | 0.131 | 265 | 1.16 (1.00–1.35) | 0.054 | 1.12 (0.93–1.35) | 0.236 |
| North | 240 | 1.28 (1.10–1.48) | 0.001 | 1.31 (1.10–1.57) | 0.003 | 153 | 1.28 (1.07–1.54) | 0.008 | 1.25 (1.01–1.55) | 0.039 |
| South | 183 | 1.11 (0.94–1.31) | 0.219 | 1.00 (0.82–1.22) | 0.994 | 144 | 1.22 (1.01–1.47) | 0.038 | 1.19 (0.94–1.50) | 0.140 |
| Wales, Scotland and Northern Ireland | 99 | 1.21 (0.98–1.50) | 0.079 | 1.32 (1.02–1.71) | 0.035 | 84 | 1.24 (0.98–1.57) | 0.068 | 1.20 (0.93–1.55) | 0.165 |
| Parity | ||||||||||
| Nulliparous | 289 | 1 | 1 | 538 | 1 | – | ||||
| One previous birth | 569 | 0.89 (0.77–1.03) | 0.120 | 0.98 (0.82–1.16) | 0.782 | 312 | 1.00 (0.87–1.15) | 0.971 | – | – |
| Two previous births | 389 | 0.90 (0.77–1.05) | 0.192 | 0.94 (0.79–1.13) | 0.525 | 141 | 1.04 (0.86–1.25) | 0.682 | – | – |
| At least three previous births | 226 | 0.72 (0.59–0.87) | 0.001 | 0.77 (0.63–0.95) | 0.013 | 68 | 0.98 (0.76–1.26) | 0.852 | – | – |
| Baseline CD4 count | ||||||||||
| ≥ 500 cells/μL | 388 | 1 | 1 | 253 | 1 | 1 | ||||
| 350–499 cells/μL | 341 | 1.15 (1.01–1.30) | 0.036 | 1.13 (0.97–1.32) | 0.109 | 225 | 1.04 (0.87–1.25) | 0.647 | 1.02 (0.84–1.23) | 0.871 |
| 200–349 cells/μL | 288 | 1.38 (1.17–1.63) | < 0.001 | 1.32 (1.12–1.55) | 0.001 | 280 | 1.24 (1.04–1.47) | 0.015 | 1.31 (1.09–1.58) | 0.003 |
| < 200 cells/μL | 144 | 1.30 (1.02–1.65) | 0.032 | 1.16 (0.93–1.45) | 0.199 | 191 | 1.54 (1.28–1.86) | < 0.001 | 1.53 (1.23–1.91) | < 0.001 |
| Baseline viral load | ||||||||||
| < 30 000 copies/mL | 899 | 1 | 1 | 679 | 1 | 1 | ||||
| 30 000–99 999 copies/mL | 207 | 1.27 (1.09–1.49) | 0.002 | 1.24 (1.05–1.46) | 0.013 | 159 | 1.14 (0.96–1.36) | 0.130 | 1.01 (0.83–1.23) | 0.904 |
| ≥ 100 000 copies/mL | 90 | 1.56 (1.13–2.16) | 0.007 | 1.43 (1.11–1.85) | 0.006 | 119 | 1.32 (1.08–1.60) | 0.006 | 1.21 (0.96–1.51) | 0.103 |
aHR, adjusted hazard ratio; CI, confidence interval; HR, hazard ratio.
An HR of > 1 indicates a shorter time to ART initiation.
The multivariable model for pregnancies in previously diagnosed women included 1074 observations (and analyses were adjusted for 996 clusters; i.e. the 1074 pregnancies occurred in 996 women).
The multivariable model for pregnancies in women diagnosed during their current pregnancy included 903 observations.
First antenatal measurement in that pregnancy, restricted to measurements prior to ART initiation.
Viral load grouping based on cut‐offs used for recommending timing of ART initiation in women not requiring treatment for their own health [4.]